| abstract |
The present invention relates to a RUNX3 gene exhibiting anticancer activity and its use. More specifically, the RUNX3 gene is essentially involved in the mechanism of TGF-β-dependent apoptosis, exhibits excellent tumorigenesis inhibitory activity, and suppresses RUNX3 gene expression in various gastric and lung cancer cell lines. It is clarified that this is due to abnormal DNA methylation in a typical CpG island near exon 1. The RUNX3 gene and its gene product of the present invention can be used not only usefully for the development of anticancer drugs, but also for the development of a test method for diagnosing cancer by measuring the degree of abnormal DNA methylation near exon 1 of the RUNX3 gene. It can be usefully used for developing a method for inducing the expression of the RUNX3 gene by regulating abnormal DNA methylation. |